Business Context and Reporting Period
This Form 8-K is a Current Report filed by AlloVir, Inc. (not Kalaris Therapeutics, Inc.) on November 15, 2021. The registrant is a Delaware corporation with its principal executive offices in Cambridge, Massachusetts. The filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this Form 8-K. The filing solely announces the availability of a corporate presentation for investor meetings.
Guidance, Outlook, and Risks
- Regulation FD Disclosure: The Company is furnishing a corporate presentation (Exhibit 99.1) intended for use in meetings with investors beginning November 15, 2021.
- Availability: The presentation is available on the Company's investor relations website.
- Legal Status: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
- Emerging Growth Company: The registrant has indicated it is an emerging growth company.
Investor Verification Checklist
- Verify the correct registrant name is AlloVir, Inc. (Ticker: ALVR), as the input metadata incorrectly referenced Kalaris Therapeutics, Inc.
- Review Exhibit 99.1 (the corporate presentation) for actual financial data, clinical updates, and strategic outlook, as this Form 8-K contains no such metrics.
- Confirm the presentation is accessible via the official investor relations website at http://allovir.com.
- Note that the presentation materials are not legally "filed" with the SEC for liability purposes under Section 18.